Edoxaban + Standard of Care (SOC)

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Disease

Conditions

Cardiac Disease

Trial Timeline

May 15, 2018 → Dec 3, 2021

NCT ID

NCT03395639

About Edoxaban + Standard of Care (SOC)

Edoxaban + Standard of Care (SOC) is a phase 3 stage product being developed by Daiichi Sankyo for Cardiac Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03395639. Target conditions include Cardiac Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03395639	Phase 3	Completed	May 15, 2018	Dec 3, 2021	Cardiac Disease

Competing Products

20 competing products in Cardiac Disease

See all competitors

Product	Company	Stage	Hype Score
regadenoson	Astellas Pharma	Pre-clinical	23
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	52
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	23
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	85
Everolimus (RAD001)	Novartis	Phase 3	77
Deferasirox and Deferoxamine	Novartis	Phase 2	52
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	85
TIN816	Novartis	Phase 2	52
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	85
Pirfenidone + Placebo	Roche	Phase 2	52
Daclizumab	Roche	Phase 1/2	41
Ranolazine + Placebo	Gilead Sciences	Phase 3	76
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
Epinephrine	Pfizer	Approved	84
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	51
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	84
BMS-986224	Bristol Myers Squibb	Phase 1	32
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	51
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	32
Sotagliflozin + Placebo	Sanofi	Phase 2	51

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved